- Sartorius Stedim’s first-quarter revenue surpassed expectations, totaling EUR 744.6 million.
- The initial revenue estimate was EUR 716 million, marking a positive difference.
- Underlying EBITDA for the first quarter reached EUR 229.0 million.
- Investor sentiment appeared strong with 13 buy recommendations.
- There were 5 hold recommendations, indicating more confidence in the company’s stable performance than skepticism.
- No sell recommendations were issued, reflecting a favorable market outlook on the stock.
A look at Sartorius Stedim Biotech Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts using Smartkarma Smart Scores have determined that Sartorius Stedim Biotech, a company specializing in developing and manufacturing laboratory technologies for various industries, has a mixed long-term outlook. With a value score of 2, the company is considered moderately priced in relation to its intrinsic value. In terms of dividends, it also scored a 2, indicating a moderate outlook. However, Sartorius Stedim Biotech scored a 3 for both growth and resilience, suggesting positive prospects for expansion and the ability to weather market challenges. Its momentum score of 3 further indicates that the company is showing steady performance trends.
In summary, Sartorius Stedim Biotech, a key player in the pharma and food industries, as well as in public research institutes and laboratories, presents a varied outlook according to Smartkarma Smart Scores. While it may be moderately valued and offer average dividends, its growth potential, resilience, and momentum point towards a promising future for the company in the long term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
